ABT.263 (navitoclax) as a Bcl-xL/Bcl-2/Bcl-w inhibitor, potentiated caspase-dependent cell death in response to 2-deoxyglucose or its combination with metformin in pediatric glioma [50]. This evidence concerns the gene BCL2 and central nervous system cancer.